Primary Research

• Conducted 31 interviews with cell therapy stakeholders worldwide, across functions from manufacturing to commercial, preclinical, and clinical

Secondary Research

• Mined data from a proprietary database of >700 cell therapy clinical development programs
• Segmented the cell therapy clinical pipeline based on vector delivery method, phase of development, cell source, cell type, and indication

Quantitative Analysis

• Developed a bottom-up 5-year forecast of the number of addressable cell-therapy pharma partners, number of commercial programs, and number of treated patients to forecast the revenue opportunity under various potential business models